Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back

Luis León-Mateos¹, María Vieito², Urbano Anido³, Rafael López López⁴, Laura Muinelo Romay⁵

Affiliations

¹ Axencia Galega de Coñecemento en Saúde (ACIS), SERGAS, Avda, Fernando de Casa Novoa, Santiago de Compostela 15707, Spain. Luis.Leon.Mateos@sergas.es.
² London Regional Cancer Program, London Health Sciences Centre, London, ON N6A 4L6, Canada. mariavieito@gmail.com.
³ Translational Medical Oncology/Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Trav. Choupana s/n, Santiago de Compostela 15706, Spain. urbanoanido@gmail.com.
⁴ Translational Medical Oncology/Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Trav. Choupana s/n, Santiago de Compostela 15706, Spain. rafa.lopez.lopez@gmail.com.
⁵ Translational Medical Oncology/Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Trav. Choupana s/n, Santiago de Compostela 15706, Spain. lmuirom@gmail.com.

PMID: 27657044
PMCID: PMC5037845
DOI: 10.3390/ijms17091580

Review

Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back

Luis León-Mateos et al. Int J Mol Sci. 2016.

. 2016 Sep 20;17(9):1580.

doi: 10.3390/ijms17091580.

Authors

Luis León-Mateos¹, María Vieito², Urbano Anido³, Rafael López López⁴, Laura Muinelo Romay⁵

Affiliations

¹ Axencia Galega de Coñecemento en Saúde (ACIS), SERGAS, Avda, Fernando de Casa Novoa, Santiago de Compostela 15707, Spain. Luis.Leon.Mateos@sergas.es.
² London Regional Cancer Program, London Health Sciences Centre, London, ON N6A 4L6, Canada. mariavieito@gmail.com.
³ Translational Medical Oncology/Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Trav. Choupana s/n, Santiago de Compostela 15706, Spain. urbanoanido@gmail.com.
⁴ Translational Medical Oncology/Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Trav. Choupana s/n, Santiago de Compostela 15706, Spain. rafa.lopez.lopez@gmail.com.
⁵ Translational Medical Oncology/Liquid Biopsy Analysis Unit, Health Research Institute of Santiago (IDIS), Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Trav. Choupana s/n, Santiago de Compostela 15706, Spain. lmuirom@gmail.com.

PMID: 27657044
PMCID: PMC5037845
DOI: 10.3390/ijms17091580

Abstract

Prostate cancer is the most common cancer in men worldwide. To improve future drug development and patient management, surrogate biomarkers associated with relevant outcomes are required. Circulating tumour cells (CTCs) are tumour cells that can enter the circulatory system, and are principally responsible for the development of metastasis at distant sites. In recent years, interest in detecting CTCs as a surrogate biomarker has ghiiukjrown. Clinical studies have revealed that high levels of CTCs in the blood correlate with disease progression in patients with prostate cancer; however, their predictive value for monitoring therapeutic response is less clear. Despite the important progress in CTC clinical development, there are critical requirements for the implementation of their analysis as a routine oncology tool. The goal of the present review is to provide an update on the advances in the clinical validation of CTCs as a surrogate biomarker and to discuss the principal obstacles and main challenges to their inclusion in clinical practice.

Keywords: circulating tumour cells; precision oncology; prostate cancer; tumour markers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

**Figure 1**
Schematic representing the value of CTCs for achieving precision oncology in patients with prostate cancer.

See this image and copyright information in PMC

Cited by

Development of a microfluidic platform for size-based hydrodynamic enrichment and PSMA-targeted immunomagnetic isolation of circulating tumour cells in prostate cancer.
Esmaeilsabzali H, Payer RTM, Guo Y, Cox ME, Parameswaran AM, Beischlag TV, Park EJ. Esmaeilsabzali H, et al. Biomicrofluidics. 2019 Feb 8;13(1):014110. doi: 10.1063/1.5064473. eCollection 2019 Jan. Biomicrofluidics. 2019. PMID: 30867880 Free PMC article.
A Prospective Correlation of Tissue Histopathology With Nucleic Acid Yield in Metastatic Castration-Resistant Prostate Cancer Biopsy Specimens.
Jimenez RE, Atwell TD, Sicotte H, Eckloff B, Wang L, Barman P, Sinnwell JP, Eiken PW, McMenomy BP, Tan W, Wang L, Carlson RE, Kohli M. Jimenez RE, et al. Mayo Clin Proc Innov Qual Outcomes. 2019 Feb 26;3(1):14-22. doi: 10.1016/j.mayocpiqo.2018.12.005. eCollection 2019 Mar. Mayo Clin Proc Innov Qual Outcomes. 2019. PMID: 30899904 Free PMC article.
Molecular and Kinetic Analyses of Circulating Tumor Cells as Predictive Markers of Treatment Response in Locally Advanced Rectal Cancer Patients.
Troncarelli Flores BC, Souza E Silva V, Ali Abdallah E, Mello CAL, Gobo Silva ML, Gomes Mendes G, Camila Braun A, Aguiar Junior S, Thomé Domingos Chinen L. Troncarelli Flores BC, et al. Cells. 2019 Jun 26;8(7):641. doi: 10.3390/cells8070641. Cells. 2019. PMID: 31247977 Free PMC article.
Liquid Biopsy for Solid Ophthalmic Malignancies: An Updated Review and Perspectives.
Martel A, Baillif S, Nahon-Esteve S, Gastaud L, Bertolotto C, Roméo B, Mograbi B, Lassalle S, Hofman P. Martel A, et al. Cancers (Basel). 2020 Nov 6;12(11):3284. doi: 10.3390/cancers12113284. Cancers (Basel). 2020. PMID: 33172021 Free PMC article. Review.

References

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013;63:11–30. doi: 10.3322/caac.21166. - DOI - PubMed
1. Heidenreich A., Bellmunt J., Bolla M., Joniau S., Mason M., Matveev V., Mottet N., Schmid H.P., van der Kwast T., Wiegel T., et al. Eau guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 2011;59:61–71. doi: 10.1016/j.eururo.2010.10.039. - DOI - PubMed
1. Cary K.C., Cooperberg M.R. Biomarkers in prostate cancer surveillance and screening: Past, present, and future. Ther. Adv. Urol. 2013;5:318–329. doi: 10.1177/1756287213495915. - DOI - PMC - PubMed
1. Soletormos G., Duffy M.J., Hayes D.F., Sturgeon C.M., Barak V., Bossuyt P.M., Diamandis E.P., Gion M., Hyltoft-Petersen P., Lamerz R.M., et al. Design of tumor biomarker-monitoring trials: A proposal by the european group on tumor markers. Clin. Chem. 2013;59:52–59. doi: 10.1373/clinchem.2011.180778. - DOI - PubMed
1. Cohen S.J., Punt C.J., Iannotti N., Saidman B.H., Sabbath K.D., Gabrail N.Y., Picus J., Morse M., Mitchell E., Miller M.C., et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008;26:3213–3221. doi: 10.1200/JCO.2007.15.8923. - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back

Affiliations

Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources